首页>
外国专利>
TREATMENT OF MUCUS HYPERSECRETION IN LUNGS BY ADMINISTRATION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGF-R) ANTAGONIST AND PHARMACEUTICAL FORMULATION
TREATMENT OF MUCUS HYPERSECRETION IN LUNGS BY ADMINISTRATION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGF-R) ANTAGONIST AND PHARMACEUTICAL FORMULATION
展开▼
机译:表皮生长因子受体(EGF-R)拮抗剂和药物制剂的治疗结核性粘膜炎
展开▼
页面导航
摘要
著录项
相似文献
摘要
Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGP receptor. The EGP-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.
展开▼